Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indomethacin versus abiraterone for abiraterone-resistant castration-resistant prostate cancer
ChiCTR2000038968Phase 4Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of indomethacin and abiraterone in prostate cancer (PCa) (2 arms), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoints: overall survival, progression-free survival and 1 more. Started Oct 2020; status: recruiting.
02
Drugs
indomethacinabiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2000038968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038968.